Home
Live Updates
Rocket Pharmaceuticals: FDA Grants Priority Review For RP-L201 : comparemela.com
Rocket Pharmaceuticals: FDA Grants Priority Review For RP-L201
Rocket Pharmaceuticals, Inc. (RCKT) announced the FDA has accepted the Biologics License Application and granted Priority Review for RP-L201, a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I.
Related Keywords
Pennsylvania ,
United States ,
Maryland ,
Florida ,
Sweden ,
Swedish ,
,
Motion Inc ,
Us Consumer Product Safety Commission ,
Volvo Group ,
Invitae Common Hereditary Cancers Panel ,
Drug Administration ,
Mack Trucks ,
United Auto Workers ,
Common Hereditary Cancers Panel ,
California Based Future Motion ,
Self Balancing Electric Skateboards ,
Product Safety Commission ,
Fda ,
Rocket Pharmaceuticals ,
comparemela.com © 2020. All Rights Reserved.